Safety Reporting
Current section refers to the item 4.11 Safety Reporting of the INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2). It provides an overview of requirements for reporting of Serious Adverse Events occurring during a clinical trial.
4.11.1 All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting. The immediate reports should be followed promptly by detailed, written reports.
The immediate and follow-up reports should identify subjects by unique code numbers assigned to the trial subjects rather than by the subjects' names, personal identification numbers, and/or addresses.
The investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.
4.11.2 Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol.
4.11.3 For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any additional requested information (e.g., autopsy reports and terminal medical reports).
Clinical Research News
다가오는 임상 시험
-
University of TennesseeWoodcock Institute for the Advancement of Neurocognitive Research and Applied Practice아직 모집하지 않음
-
University of Texas Southwestern Medical CenterMerck Sharp & Dohme LLC아직 모집하지 않음
-
Universita di VeronaAzienda Ospedaliera Universitaria Integrata Verona아직 모집하지 않음류마티스 관절염 | 무릎의 퇴행성 관절 질환이탈리아
-
University of Wisconsin, MadisonAlkermes, Inc.아직 모집하지 않음
-
Virginia Commonwealth University아직 모집하지 않음
-
Weill Medical College of Cornell UniversityNational Institute of Mental Health (NIMH); Icahn School of Medicine at Mount Sinai아직 모집하지 않음케타민 | fMRI | 우울증 - 주요 우울 장애 | rTMS | 치료 저항성 우울증(TRD)미국
-
Weill Medical College of Cornell UniversityBD2 LLC아직 모집하지 않음fMRI | 양극성 장애(BD) | rTMS | 양극성 1 우울증미국
-
Yale UniversityNational Institute of Mental Health (NIMH)아직 모집하지 않음
-
Cambridge University Hospitals NHS Foundation TrustUniversity of Cambridge모병갈색 세포종 | 크롬친화세포종/부신경절종 | 갈색 세포종, 전이성 | 갈색 세포종 악성 | 페로 크로 모세포종 및 paraganglioma (PPGL)영국
-
Carl Zeiss Meditec-Dublin CoCe모병망막앞막 | 망막질환 | 건기 관련 황반 변성 | 유리체 망막 이상 | Macular Abnormalities | Intraretinal Hyporeflective Space | Subretinal Hyporeflective Space | IS/OS (Ellipsoid Zone) Disruption | Retinal Pigment Epithelium (RPE) Elevation | Retinal Pigment Epithelium (RPE) Atrophy미국
-
Celest Therapeutics (Shanghai) Co., Ltd.The First Affiliated Hospital of Anhui Medical University모병
Clinical Research Jobs
-
Czechia - Brno
-
Belgium - Leuven
-
United Kingdom - Tranent
-
Romania - Bucharest
-
United StatesCanada - Québec - Quebec
-
United Kingdom - Guildford
-
India - Bengaluru
-
United States - North Carolina - Morrisville
-
China